Compare FirstEnergy Corp. (FE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs TG Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $45.11 (market cap $25.95B), while TG Therapeutics Inc trades at $54.88 (market cap $8.16B). The key difference: FirstEnergy Corp. is far larger — about 3.2× TG Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 4.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and TG Therapeutics Inc for 16 Days on average.
| FE | TGTX | |
|---|---|---|
Market Cap | $25.95B | $8.16B |
Volume | 5,643,833 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $51.91 | $59.06 |
52-Week Low | $43.04 | $26.94 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $54.87B | $8.37B |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.93, up 0.79% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, while Q1 beat estimates. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analysts maintain a Moderate Buy rating with a $52.80 price target, representing 17.5% upside. Recent news highlights the $36B Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with steady revenue growth and dividend yield, though elevated debt levels and inconsistent earnings performance pose risks. The stock's current valuation at 23.98 P/E appears reasonable given the utility sector's defensive characteristics. Upside potential exists if the company can consistently meet earnings expectations and execute its capital investment program effectively.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
